Grünenthal Group

Grünenthal donates 400.000€ and provides pain treatment medicine to Ukraine

Share

Aachen, Germany, 7 March 2022 – Grünenthal, an international science-driven pharmaceutical company, announced that it has donated 400.000€ to the Red Cross to support humanitarian relief efforts in Ukraine and Eastern Europe. In addition, Grünenthal partners with Action Medeor and the University Hospital of RWTH Aachen to provide urgently needed pain medication to the region. The first transport with medicine is set to leave Aachen this week.

“We are shocked and saddened by the attack on Ukraine. Our full solidarity is with Ukraine’s people and everyone affected, no matter where they come from. Grünenthal will contribute to ensuring urgently needed medical care”, said Gabriel Baertschi, CEO of Grünenthal.

Contacts

For further information, please contact:

Fabia Kehren, Head External Communications & Editorial Management
Tel.: +49 241 569-3269
Fabia.Kehren@grunenthal.com
Grünenthal GmbH, 52099 Aachen, Germany

About Grünenthal Group

Grünenthal Group
Grünenthal Group

Aachen, Germany

About Grünenthal

Grünenthal is a global leader in pain management and related diseases. As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better and innovation is our passion. We are focusing all of our activities and efforts on working towards our vision of a world free of pain.

Grünenthal is headquartered in Aachen, Germany, and has affiliates in 29 countries across Europe, Latin America and the US. Our products are available in more than 100 countries. In 2020 Grünenthal employed around 4,500 people and achieved sales of € 1.3 bn.

More information: www.grunenthal.com

Follow us on:

LinkedIn: Grunenthal Group

Instagram: grunenthal

Subscribe to releases from Grünenthal Group

Subscribe to all the latest releases from Grünenthal Group by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Grünenthal Group

Grünenthal starts Phase III trials for resiniferatoxin in osteoarthritis-related pain18.8.2022 14:20:25 EEST | Press release

Global Phase III programme to enable marketing authorisation in the EU, the US and Japan for an innovativenon-opioid investigational medicine. The programme will be conducted across approx. 200 study sites and include more than 1800 patients suffering from pain associated with osteoarthritis. Globally, more than 300 million patients suffer from osteoarthritis[1]. The global osteoarthritis market is expected to grow to approximately $11.0 billion in 2025[2]. Aachen, Germany – 18 August 2022 –Grünenthal announced today that the company has enrolled the first patient in its global clinical Phase III programme for resiniferatoxin (RTX). RTX is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist, with a well-validated mechanism of action. The discovery of TRPV1 was awarded the Nobel Prize of Physiology or Medicine in 2021. If approved, resiniferatoxin may provide patients with long-lasting pain relief with a favourable safety profile. Grünenthal’s Phase III programme wi

Grünenthal acquires testosterone treatment NebidoTM from Bayer14.7.2022 09:43:56 EEST | Press release

Grünenthal acquires NebidoTM from Bayer AG for up to € 500 million. The product is expected to add about € 100 million to Grünenthal’s EBITDA in 2023. NebidoTM is the gold standard for the treatment of male hypogonadism associated with testosterone deficiency. It is available to patients in over 80 markets worldwide. Grünenthal has invested over € 2 billion in successful M&A transactions over the last years, resulting in a significantly strengthened profitability.

Grünenthal, Uniklinik RWTH Aachen and RTWH Aachen University collaborate to advance pain research7.7.2022 10:05:00 EEST | Press release

Aachen, Germany – 7 July 2022 – Grünenthal, Uniklinik RWTH Aachen and RWTH Aachen University announced a collaboration to advance the development of next-generation pain medicines. The collaboration involves the institutes of Dr Angelika Lampert, Professor of Physiology at the Uniklinik RWTH Aachen and Dr Marc Spehr, Lichtenberg-Professor for Chemosensation at the RWTH Aachen University. The partners strive to develop a range of translational research tools and humanised preclinical models to enhance target validation.

Grünenthal and NovaQuest enter agreement to advance the resiniferatoxin global Phase III program in osteoarthritis29.3.2022 13:05:00 EEST | Press release

Aachen, Germany, and Raleigh, North Carolina - USA, 29 March 2022 – Grünenthal and NovaQuest announced today that they have entered into an agreement to advance the global clinical Phase III programme of Grünenthal's asset resiniferatoxin (RTX). The investigational medicine is being developed with the aim of providing patients suffering from pain associated with osteoarthritis with a well-tolerated, non-opioid therapy option that is intended to provide long-lasting pain relief and functional improvement of the affected joints.